Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://clinicaltrials.gov/ct2/show/NCT01217437

2. Intervention

   Bevacizumab

3. Intervention

   Irinotecan hydrochloride

4. Intervention

   Temozolomide

5. Resource Description

   There is no current standard treatment for recurrent/refractory medulloblastoma/PNET. Recurrent/refractory medulloblastoma/PNET is difficult to treat successfully. Previous studies have shown that the combination of the medicines temozolomide and irinotecan have activity against recurrent medulloblastoma/PNET. This study will use temozolomide and irinotecan to try to improve or slow the growth of recurrent/refractory medulloblastoma/PNET. Some of the participants in this study will also receive the medicine bevacizumab. Bevacizumab works differently than the medications temozolomide and irinotecan. Adding bevacizumab to treatment with temozolomide and irinotecan is experimental.

6. Additional Name

   Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

7. Contact

   Berenberg, Jeffrey

8. PI

   Wilkinson, Robert, M.D.

9. Topic

   medulloblastoma

10. Study Population

    Patient Age: Patients must be less than or equal to 21 years of age .For patients with recurrent or refractory medulloblastoma/PNET tumor

11. Funded by

    Children's Oncology Group

12. Phase

    Phase 2 clinical trial

13. Performed by

    Clinical Protocol & Data Management Shared Resource